Immunooncology Market Slated to Bring in US$ 27,846.3 Mn by End of 2017-2025

Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and surgery, doctors around the globe are increasingly prescribing immunotherapy to cancer patients. Immuno-oncology therapies have low toxicity, making it easier for the patients to undergo such treatment procedures. Increasing clinical approval of immunotherapy drugs continues to support speedy adoption of immuno-oncology treatments while higher investments to further improve immunotherapies is anticipated to create greater market opportunities for drug makers. Persistence Market Research (PMR) is its latest report projects that the global market for immune-oncology is set to witness a CAGR of 16.5% between 2016 and 2025, to reach a valuation of US$ 27,846.3 Mn by the end of the forecast period.
Request For Report Sample@ https://www.persistencemarketresearch.com/samples/11329
Collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is a key factor driving the overall immune-oncology market. However, high drug pricing, development costs and limited technical expertise are some of the challenges likely to dampen the surging spirit of the market over 2025.
Demand for Immune Checkpoint Inhibitors to Remain Robust
Currently, immune checkpoint inhibitor therapy is widely used for treating several carcinogenic disorders. Immune checkpoint inhibitor drugs help the body fight against certain proteins that are normally used by various tumors to suppress immune responses. Sales revenue from immune checkpoint inhibitors drugs is anticipated to reach US$ 7,321.7 Mn by 2017-end. Of late, a number immune checkpoint inhibitor drugs have been approved by the US FDA including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1). Demand for these drugs is expected to further gain traction, owing to a significant investment by biopharmaceutical companies in developing a robust pipeline. Meanwhile, immune system modulator is the second most preferred immune-oncology therapy and is expected to create an incremental opportunity of US$ 659.9 Mn between 2017 and 2025. Two major approved drugs that fall in this category include interferons and interleukins.
Request For Report Table of Content (TOC)@ https://www.persistencemarketresearch.com/methodology/11329
Based on therapeutic area, demand for immune-oncology therapeutics for melanoma will remain high throughout the forecast period. By end user, hospitals account for the largest revenue share of the market and are expected to represent around US$ 5,557.1 Mn by 2017-end.
Amongst regions, the immuno-oncology market in North America accounted for a revenue share of around 67.1% in 2016. The region’s market is expected to witness a strong CAGR of 17.1% during the assessment period and retain its top position. In terms of revenue, the US dominates the North America immuno-oncology market and is projected to continue to do so in 2017 and beyond owing to the presence of prominent drug manufacturing companies in the country.
Competitive Landscape
PMR is its report has profiled some of the leading companies operating in the global immuno-oncology market, which includes Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Dendreon Corporation, F.Hoffmann-La Roche, Merck & Co., Inc. Novartis AG, Pfizer, Inc., Sanofi. In terms of revenue share, Bristol-Myers Squibb (BMS) was ranked at the top in 2016, thanks to the success of its blockbuster products Opdivo and Yervoy.
Know More About Report@ https://www.persistencemarketresearch.com/mediarelease/immunooncology-market.asp

Covaxin vs Covishield: A Comparison between the Covid-19 Vaccines of India

The second wave of Covid-19 pandemic has reminded people the hard times faced during the coronavirus outbreak in 2020 in India. However, there is still an upper hand in 2021 in the fight against Covid-19, and this can be attributed to the nationwide vaccination drive. It has been clear that getting vaccinated is one of the simple yet effective ways to combat the pandemic. Vaccination helps in producing antibodies and boosts the immune system to fight against any infection. Besides, getting Covid-19 vaccination is known to reduce the severity of the infection and helps in lowering the chances of getting hospitalized due to the severe infection caused due to Covid-19. Covaxin Vs Covishield Currently, the Indian Government has approved two vaccines namely Covaxin and Covishield to fight Covid-19. Many people are wondering which vaccine is better among the two, and here is a quick read to help them answer all their queries. Covaxin Covaxin was given approval for by the Indian

Contactless Payment Market size share growth analysis market demand

Contactless payment, also called as a tap-and-go system is a secure mode where the transactions are done using technologies such as NFC (near field communication), RFID (radio frequency identification), infrared, and bluetooth. Contactless payment is hassle-free and convenient for customers as it takes only one-tenth of the time taken by the old-style electronic transaction.Contactless payment is becoming popular owing to its benefits such as secure and fast payments without any need for cash or identifying details. Initially, these type of payments or cards were used for the purpose oftravelling tickets only. But today, this technology has evolved and is helping customers to make payments for almost anything. However, the permissible amount for a contactless payment varies by country and by the bank. Access to PDF Sample Report Here! @ https://www.researchdive.com/download-sample/181 Recent Developments in the Contactless Payment Industry As per a Research Dive blog, the digital e

Development: Aerospace 3D Printing Market Strategy Planning by Top Manufacturers

Aerospace 3D Printing Market Analysis 2026: According to a study of the Research Dive, aerospace 3D printing market forecast shall cross $5,933.4 million by 2026 , growing at a CAGR of 26.8% during forecast period. Aerospace 3D printing is primarily used to increase the efficiency of A&D supply chain, reduction of storage costs of inventory and waste production materials. Furthermore, the Aerospace 3D printing industry is focusing more on creating parts of aircraft that are lighter and stronger than parts made by using traditional manufacturing. Astonishing advantages of 3D printings in the supply chain of the aerospace and defense industry are projected to surge in the global market. In addition, the financial support provided by the government and non-government organizations across the globe is also driving the 3D printing in aerospace industry. For instance, National Aerospace Technology Exploitation Programme grants £140,000 funds for UK based company Sigma Components

Industrial Research World

Search This Blog